<DOC>
	<DOCNO>NCT02611778</DOCNO>
	<brief_summary>The purpose study determine efficacy safety biosimilar ranibizumab FYB201 comparison Lucentis patient neovascular age-related macular degeneration .</brief_summary>
	<brief_title>Efficacy Safety Biosimilar Ranibizumab FYB201 Comparison Lucentis Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 50 year either gender Signed inform consent form must obtain studyrelated procedure perform Willingness ability undertake schedule visit assessment Women must postmenopausal surgically sterile Newly diagnose , angiographically document , primary active Choroidal Neovascularization ( CNV ) lesion secondary agerelated macular degeneration ( AMD ) Sufficiently clear ocular medium adequate pupillary dilation permit good quality ocular image Exclusion criterion : Employees clinical study site , individual directly involve conduct study immediate family member thereof , prisoner , person legally institutionalize Any previous treatment intravitreal ( IVT ) antivascular endothelial growth factor ( VEGF ) agent either eye History vitrectomy , macular surgery surgical intervention AMD study eye History IVT treatment corticosteroid device implantation within six month prior Screening study eye Prior treatment verteporfin ( photodynamic therapy ) , transpupillary thermotherapy , radiation therapy , retinal laser treatment ( e.g . focal laser photocoagulation ) study eye Topical ocular corticosteroid administer least 30 consecutive day within three month prior Screening Any intraocular surgery ( include cataract surgery ) study eye within three month prior Screening Sub intraretinal hemorrhage comprise 50 % entire lesion study eye Fibrosis atrophy involve center fovea influence central visual function study eye CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Retinal pigment epithelial tear involve macula study eye History fullthickness macular hole study eye History retinal detachment study eye Current vitreous hemorrhage study eye Spherical equivalent refractive error study eye demonstrate 8 diopter myopia For patient undergone prior refractive cataract surgery study eye , preoperative refractive error study eye exceed 8 diopter myopia History corneal transplant study eye Aphakia study eye . Absence intact posterior capsule allow occur result YttriumAluminiumGarnet ( YAG ) laser posterior capsulotomy association prior posterior chamber intraocular lens ( IOL ) implantation Active recent ( within 4 week ) intraocular inflammation clinical significance study eye active infection anterior segment ( exclude mild blepharitis ) include conjunctivitis , keratitis , scleritis , uveitis endophthalmitis Uncontrolled hypertension glaucoma study eye ( defined intraocular pressure ( IOP ) ≥30 mm Hg , despite treatment antiglaucomatous medication ) Ocular disorder study eye ( i.e . retinal detachment , preretinal membrane macula cataract significant impact visual acuity ) time enrollment may confound interpretation study result compromise visual acuity Any concurrent intraocular condition study eye ( e.g . glaucoma , cataract diabetic retinopathy ) , opinion Investigator , would either require surgical intervention study prevent treat visual loss might result condition affect interpretation study result . Use investigational drug ( exclude vitamin , mineral ) within 30 day 5 halflives Screening , whichever longer Any type advance , severe unstable disease , include medical condition ( control uncontrolled ) could expect progress , recur , change extent may bias assessment clinical status patient significant degree put patient special risk Stroke myocardial infarction within three month prior Screening Presence uncontrolled systolic blood pressure &gt; 160 mmHg uncontrolled diastolic blood pressure &gt; 100 mmHg Known hypersensitivity investigational drug ( ranibizumab component ranibizumab formulation ) drug similar chemical class fluorescein component fluorescein formulation Current plan use systemic medication know toxic lens , retina optic nerve , include deferoxamine , chloroquine/hydroxychloroquine ( Plaquenil® ) , tamoxifen , phenothiazine ethambutol History recurrent significant infection and/or current treatment active systemic infection Pregnancy lactation Systemic treatment long act corticosteroid ( 10 mg prednisolone equivalent ) last six month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>